Abstract Purpose of the study Elucidating evolutionary trajectories of cancers allows us to understand the key events, and the order in which they occur, throughout their development. This can help us to find important associations with tumor progression and prognosis. Our aim was to perform de novo identification of the evolutionary trajectories within Sherlock-lung, with a dataset containing the largest collection of lung cancer in never smokers (LCINS) samples ever analyzed. Experimental procedures Our Plackett-Luce ordering model utilized copy number data from Battenberg and mutation cancer cell fraction (CCF) data from DPClust. Frequently-occurring copy number events and driver mutations are ordered within each sample using their copy number states and CCFs. An aggregate ordering is then calculated for a sample set. Mixture model analysis identifies subsets of samples displaying distinct orders of events, uncovering diverse evolutionary trajectories within a tumor set. Dataset The Sherlock-lung whole genome sequencing dataset (n=1217) was filtered to the samples that allowed us to identify subclonal expansions. Samples required at least 10 reads per chromosome copy and a minimum cellularity of 30%. This provided 458 LCINS samples of various histologies. 155 smoker samples were also analyzed for comparison. Results We identified two subsets of LCINS tumors following distinct evolutionary trajectories. The “loss-based” subset commonly saw whole genome duplication (WGD) combined with copy number losses occurring earlier, and at higher prevalence, than gains. Contrastingly, in the “gain-based” subset, WGD was relatively rare but ploidy increased via copy number gains, which were more prevalent than losses. Interestingly, these different trajectories converged on similar overall copy number states. The loss-based subset had a higher mutational burden and a higher proportion of the genome altered, and followed a more smoker-like trajectory than the gain-based subset. Considering these differences alongside the convergence in copy number states, it is intriguing that survival times were similar between the two subsets. Copy number events defined the difference between the two trajectories. However, driver mutations also played important roles in tumor evolution in LCINS. TP53 and EGFR mutations were associated with greater genomic instability. Conversely, KRAS mutations were associated with more stable genomes. Samples with early clonal mutations in TP53, ERBB2, and PIK3CA, as well as those with a copy number gain of ERBB2, exhibited shorter survival times. Conclusions Two distinct evolutionary trajectories of LCINS were identified by de novo Plackett-Luce event ordering analysis. The contrast between the subgroups was defined by different paths of copy number activity, but they ultimately converged on similar overall copy number states and outcomes. Key early driver mutations influenced genomic instability and survival times. Citation Format: Christopher Wirth, Tongwu Zhang, Wei Zhao, Phuc Hoang, Jian Sang, Nathaniel Rothman, Marcos Díaz-Gay, Ruxandra Teslo, Naser Ansari-Pour, Máire Ní Leathlobhair, Iliana Peneva, William Eagles, Lixing Yang, Ludmil Alexandrov, David C. Wedge, Maria Teresa Landi. Evolutionary trajectories of lung cancer in never smokers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB228.
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of the disease. As part of The Cancer Genome Atlas project, we report here an integrated analysis of 131 urothelial carcinomas to provide a comprehensive landscape of molecular alterations. There were statistically significant recurrent mutations in 32 genes, including multiple genes involved in cell-cycle regulation, chromatin regulation, and kinase signalling pathways, as well as 9 genes not previously reported as significantly mutated in any cancer. RNA sequencing revealed four expression subtypes, two of which (papillary-like and basal/squamous-like) were also evident in microRNA sequencing and protein data. Whole-genome and RNA sequencing identified recurrent in-frame activating FGFR3-TACC3 fusions and expression or integration of several viruses (including HPV16) that are associated with gene inactivation. Our analyses identified potential therapeutic targets in 69% of the tumours, including 42% with targets in the phosphatidylinositol-3-OH kinase/AKT/mTOR pathway and 45% with targets (including ERBB2) in the RTK/MAPK pathway. Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalities.
Abstract Somatic structural variations (SVs) are common in cancer. Although a small fraction of SVs in breast and ovarian cancers can be attributed to homologous recombination deficiency, the underlying molecular mechanisms for the vast majority of somatic SVs remain unclear. Here, we focus on the roles of transcription and DNA replication collisions in genomic instability in cancer. Such collisions are unavoidable in cells since both transcription and replication use the same DNA as template. We hypothesized that transcription replication collisions (TRCs), if not properly repaired, would lead to collapsed replication forks and result in SVs. To this end, we studied somatic SVs in 6193 high-coverage whole-genome sequenced primary and metastatic tumors from three independent pan-cancer cohorts. A total of 13 conserved SV signatures, representing independent molecular mechanisms, were deconvoluted from these cohorts using non-negative matrix factorization approach. We detected replicated-strand bias, the expected footprint of transcription-replication collision, in large tandem duplications (TDs) across multiple cohorts. This bias was only observed in expressed genes, consistent with TRCs depending on transcription activity. Large TDs were abundant in female-specific (breast, ovarian and uterus), upper gastric-intestinal tract, and prostate cancers. They were associated with CDK12 mutations and worse patient survival. CDK12 is a cyclin-dependent kinase, a key regulator of transcription elongation and termination. Deleting or suppressing CDK12 using CRISPR-Cas9 in prostate cell lines increased RNA:DNA hybrids (R-loops), promoted TRCs, and ultimately led to large TDs. Finally, we found that cells lacking CDK12 were sensitive to WEE1, CHK1 and ATR inhibitors. In summary, our data suggest that large TDs in cancer form due to impaired TRC repair and can be used as a biomarker for prognosis and treatment. Citation Format: Lixing Yang. Data-driven discoveries of molecular mechanism and therapeutic vulnerabilities of CDK12 mutant tumors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B006.
Additional file 5: Table S4. Target up-regulating geneUIB fusions, investigated with the scenario in which an intergenic breakpoint is located up to 4 Mb upstream of a target gene.
Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas.
